bevacizumab irinotecan glioblastoma bc cancer

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
bevacizumab irinotecan glioblastoma bc cancer	0.48	0.6	5315	83	45
bevacizumab	1.34	0.3	7174	48	11
irinotecan	0.87	0.6	8973	74	10
glioblastoma	0.38	0.1	286	48	12
bc	1.31	0.6	9544	90	2
cancer	1.23	0.4	4525	44	6

Keyword	CPC	PCC	Volume	Score
bevacizumab irinotecan glioblastoma bc cancer	1.73	0.4	5809	85
irinotecan bevacizumab glioblastoma protocol	0.66	0.5	1723	26
bc cancer atezolizumab bevacizumab	1.22	0.6	2514	23
bevacizumab glioblastoma fda approval	1.83	0.1	2963	83
bevacizumab in lung cancer	0.35	0.9	8311	64
bevacizumab in colorectal cancer	1.76	0.5	694	37
bevacizumab and pembrolizumab glioblastoma	1.07	0.8	9242	13
capecitabine irinotecan and bevacizumab	0.69	0.5	5572	72
bevacizumab for colon cancer	0.29	0.4	4797	33
bevacizumab erlotinib renal cell carcinoma	1.25	1	8152	33
bevacizumab metastatic colorectal cancer	1.76	0.7	4765	89
bevacizumab right side colon cancer	1.34	0.6	8835	30
irinotecan single agent bc cancer	0.4	0.2	9836	32
bevacizumab capecitabine colorectal cancer	1.19	1	6884	44
bevacizumab for the treatment of angiosarcoma	0.91	0.3	4602	4
lomustine and bevacizumab glioblastoma	0.89	0.5	3583	3
bevacizumab in ovarian cancer	0.21	0.1	8836	94
bevacizumab chemotherapy or immunotherapy	1.61	0.2	4664	78
nivolumab ipilimumab colorectal cancer	1.85	0.7	6437	71
bevacizumab-bvzr	0.26	0.6	4380	87
nivolumab ipilimumab lung cancer	1.56	0.3	4028	36
nivolumab for the treatment of cancer	1.87	0.2	6269	42
nivolumab ipilimumab hepatocellular carcinoma	0.1	0.7	4433	90